| Valued Reader, This just out from Mauldin Economics (read full article here): Special Release Bulletin, Saturday, November 28th And the current edition, released November 19, continues to impress with a small-cap health technology company with a game-changing approach to targeting cancer cells using a patented gene-based therapy. The stock is currently trading at under $5, with a near-term upside of $12 or more, no matter what the overall economy does…. Chris Wood, editor of Healthy Returns and 20-year market veteran specializing in the healthcare and biotech sectors, JUST released his latest stock recommendation. This stock, currently a steal at around five bucks, is set to soar 140% from its current level. That means any amount you invested could more than double. … $1,000 could grow to $2,400 … $5,000 could transform to $12,000 The time to enter this trade is now, and we have some great news… We’ll give you the ticker for free. You see, this year for the Thanksgiving holiday, we decided to thank our loyal readers in a unique way... By giving away $1.1 million in Premium Research—no strings attached. And all you have to do to claim your portion, and uncover Chris's important healthcare pick is… Click here, accept your All Access Pass, and create a password. No entering your credit card number. Just full and unfettered access to three of our most popular premium research publications—including Chris Wood’s groundbreaking publication Healthy Returns—for free. But you have to hurry. There are only two days left to use this pass. Please take advantage of this incredible opportunity while it remains open. Show me my free premium research and over 30 income-generating investments I could add to my portfolio today. Sincerely,
Mauldin Economics P.S. After you claim your pass and enter the member area, visit Healthy Returns first to download Chris’s most recent newsletter: “This High-Tech “SPEAR” Kills Cancer Cells on Sight.” In it, you’ll uncover his pick predicted to return 140%, and the valuable research that shows you why NOW is the time to buy. | 